With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1083224-23-0,5-(2,4-Difluorophenyl)isoxazole-3-carboxylic acid,as a common compound, the synthetic route is as follows.
General procedure: To a solution of rac-(3R*,4R*)-4-amino-1-benzyl-piperidine-3-carboxylic acid methyl ester (10.00 g, 33.4 mmol) in DMF (200 mL) is added 5-(2,4-difluorophenyl)isoxazole-3-carboxylic acid (7.74 g, 33.4 mmol). DIPEA (24.5 mL, 140 mmol) is then added followed by HATU (13.32 g, 35 mmol). The reaction mixture is stirred for 1 h. The reaction mixture is concentrated, diluted with DCM (750 mL) and treated with aq. sat. NaHC03 (600 mL). The organic layer is dried over MgS04 and evaporated. The crude residue is purified by prep. LC- MS in basic conditions to give the title compound; LC-MS method D tR = 1.14 min; [M+H]+ = 456.18.
1083224-23-0, The synthetic route of 1083224-23-0 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; IDORSIA PHARMACEUTICALS LTD; AISSAOUI, Hamed; GUERRY, Philippe; LEHEMBRE, Francois; POTHIER, Julien; POUZOL, Laetitia; RICHARD-BILDSTEIN, Sylvia; YUAN, Shuguang; (273 pag.)WO2018/19929; (2018); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem